Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

66.7%

2 terminated/withdrawn out of 3 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

200%

2 of 1 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2
2(66.7%)
Phase 1
1(33.3%)
3Total
Phase 2(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT00429858Phase 2Terminated

Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer

Role: lead

NCT02487277Phase 2Terminated

PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma

Role: lead

NCT01383538Phase 1Completed

FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma

Role: lead

All 3 trials loaded